Evidence map›Paper›PMID 38899562›Full record

ArticleCell proliferation2024

Modelling bone metastasis in spheroids to study cancer progression and screen cisplatin efficacy.

Ceri-Anne E Suurmond, Sander C G Leeuwenburgh, Jeroen J J P van den Beucken

Abstract read
In one paragraph

Article in Cell proliferation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ceri-Anne E SuurmondDentistry-Regenerative Biomaterials, Radboudumc, Nijmegen, The Netherlands.ORCID https://orcid.org/0009-0005-7715-888X
Sander C G LeeuwenburghDentistry-Regenerative Biomaterials, Radboudumc, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0003-1471-6133
Jeroen J J P van den BeuckenDentistry-Regenerative Biomaterials, Radboudumc, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0002-0301-1966

Funding

Nederlandse Organisatie voor Wetenschappelijk Onderzoek 17835
6 · The paper itself

Abstract

Most bone metastases are caused by primary breast or prostate cancer cells settling in the bone microenvironment, affecting normal bone physiology and function and reducing 5-year survival rates to 10% and 6%, respectively. To expedite clinical availability of novel and effective bone metastases treatments, reliable and predictive in vitro models are urgently required to screen for novel therapies as current in vitro 2D planar mono-culture models do not accurately predict the clinical efficacy. We herein engineered a novel human in vitro 3D co-culture model based on spheroids to study dynamic cellular quantities of (breast or prostate) cancer cells and human bone marrow stromal cells and screen chemotherapeutic efficacy and specificity of the common anticancer drug cisplatin. Bone metastatic spheroids (BMSs) were formed rapidly within 24 h, while the morphology of breast versus prostate cancer BMS differed in terms of size and circularity upon prolonged culture periods. Prestaining cell types prior to BMS formation enabled confocal imaging and quantitative image analysis of in-spheroid cellular dynamics for up to 7 days of BMS culture. We found that cancer cells in BMS proliferated faster and were less susceptible to cisplatin treatment compared to 2D control cultures. Based on these findings and the versatility of our methodology, BMS represent a feasible 3D in vitro model for screening of new bone cancer metastases therapies.

Indexed as

Antineoplastic AgentsBone NeoplasmsBreast NeoplasmsCisplatinCoculture TechniquesProstatic NeoplasmsSpheroids, CellularCell Line, TumorCell ProliferationDisease ProgressionDrug Screening Assays, AntitumorFemaleHumansMaleMesenchymal Stem CellsAntineoplastic AgentsCisplatin

Identifiers

PMID38899562
PMCPMC11503253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.